Abstract
Background There is a growing interest in the use of targeted and immunotherapies in oncology. However, the assessment of side effects can be different due to interpretation of patients’ health status by healthcare professionals in oncology outpatient clinics. Objective To demonstrate the differences in the assessments of side effects conducted independently by a clinical pharmacist and nurses in patients who receive targeted therapies at an oncology outpatient clinic. Setting The study was conducted at the University Oncology Hospital in an outpatient clinic from October 2015 to March 2016. Method Patients receiving ipilimumab, nivolumab, pembrolizumab, bevacizumab, panitumumab or cetuximab during study period were included. The assessment of side effects was conducted by a pharmacist and nurse independently using the NCI-CTCAE version-2. Main outcome measure To compare the severity assessments of side effects between a clinical pharmacist and nurses in an outpatient clinic. Results During the study, 204 visits for 43 patients with a total of 5508 side effect assessments were recorded where 1137 (20.64%) assessments were graded differently. Out of 1137 assessments, 473 of them were graded higher by a clinical pharmacist whereas 664 were graded higher by nurses. Statistically significant differences were detected in the assessment of vomiting, taste changes, sense changes, alopecia, fatigue, mood changes, anxiety, hearing impairment, and allergic reactions. Conclusion An assessment of side effects by healthcare providers in patients with cancer may be challenging due to an increased workload in clinics and undistinguishable symptoms of side effects and cancer itself. Therefore, a new care model which increases an interprofessional communication may improve pharmaceutical care in oncology outpatient clinics.
Similar content being viewed by others
References
Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2–negative (or unknown) advanced breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(29):3307–29.
Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12(4):237–51.
Bonifazi M, Rossi M, Moja L, Scigliano VD, Franchi M, La Vecchia C, et al. Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety. Oncologist. 2012;17(1):117–24.
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28.
Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004–12.
Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: Panitumumab (Vectibix™). Oncologist. 2007;12(5):577–83.
Ibrahim EM, Abouelkhair KM. Clinical outcome of panitumumab for metastatic colorectal cancer with wild-type KRAS status: a meta-analysis of randomized clinical trials. Med Oncol. 2011;28:S310–7.
R Liang, L Zheng. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials. Drug Des Dev Therapy. 2015;9:4471.
McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. 2015;33(18):2013–20.
O’Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010;21(8):1712–7.
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.
Taugourdeau-Raymond S, Rouby F, Default A, Jean-Pastor MJ. Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database. Eur J Clin Pharmacol. 2012;68(7):1103–7.
Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–30.
Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab. Cancer. 2013;119(9):1675–82.
Zhang D, Ye J, Xu T, Xiong B. Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis. J Chemother. 2013;25(3):170–5.
Park M-H, Jo C, Bae EY, Lee E-K. A comparison of preferences of targeted therapy for metastatic renal cell carcinoma between the patient group and health care professional group in South Korea. Value Health. 2012;15(6):933–9.
Atkinson TM, Li Y, Coffey CW, Sit L, Shaw M, Lavene D, et al. Reliability of adverse symptom event reporting by clinicians. Qual Life Res. 2012;21(7):1159–64.
Mulders M, Vingerhoets A, Breed W. The impact of cancer and chemotherapy: perceptual similarities and differences between cancer patients, nurses and physicians. Eur J Oncol Nurs. 2008;12(2):97–102.
Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006;7(11):903–9.
Common Toxicity Criteria: Version 2.0. In: Institute NC, editor. 1999.
Papastavrou E, Charalambous A, Vryonides S, Eleftheriou C, Merkouris A. To what extent are patients’ needs met on oncology units? The phenomenon of care rationing. Eur J Oncol Nurs. 2016;21:48–56.
Ribed A, Romero-Jiménez RM, Escudero-Vilaplana V, Iglesias-Peinado I, Herranz-Alonso A, Codina C, et al. Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction. Int J Clin Pharm. 2016;38(2):280–8.
Periasamy U, Mohd Sidik S, Rampal L, Fadhilah SI, Akhtari-Zavare M, Mahmud R. Effect of chemotherapy counseling by pharmacists on quality of life and psychological outcomes of oncology patients in Malaysia: a randomized control trial. Health Qual Life Outcomes. 2017;15(1):104.
Walter C, Mellor JD, Rice C, Kirsa S, Ball D, Duffy M, et al. Impact of a specialist clinical cancer pharmacist at a multidisciplinary lung cancer clinic. Asia-Pac J Clin Oncol. 2016;12(3):e367–74.
Berglund CB, Gustafsson E, Johansson H, Bergenmar M. Nurse-led outpatient clinics in oncology care—patient satisfaction, information and continuity of care. Eur J Oncol Nurs. 2015;19(6):724–30.
Fortner B, Baldwin S, Schwartzberg L, Houts AC. Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation. J Pain Symptom Manag. 2006;31(3):207–14.
Abueg KD. Interprofessional management of toxicities related to cancer precision medicine. Semin Oncol Nurs. 2017;33(4):376–83.
Ibraheem AF, Awolude OA, Habeebu M-M, Sowunmi AC, Olaniyi PA, Olopade OI, et al. Formal assessment of teamwork among cancer health care professionals in 3 large tertiary centers in Nigeria. J Clin Oncol. 2017;35(15_suppl):e18126-e.
Lee CT, Doran DM, Tourangeau AE, Fleshner NE. Perceived quality of interprofessional interactions between physicians and nurses in oncology outpatient clinics. Eur J Oncol Nurs. 2014;18(6):619–25.
Acknowledgements
The authors wish to thank all clinic nurses, medical oncology consultants (Professor Kilickap and Professor Erman from the Hacettepe University Cancer Institute) and the pharmacist, Kelleci-Cakir (Hacettepe University, Department of Clinical Pharmacy) for their greatly appreciated support in this study.
Funding
This work was funded by Hacettepe University Scientific Research Coordination Unit. Project Number: TKG-2016-11039.
Conflicts of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Appendix
Appendix
See Table 1.
Rights and permissions
About this article
Cite this article
Bayraktar-Ekincioglu, A., Kucuk, E. The differences in the assessments of side effects at an oncology outpatient clinic. Int J Clin Pharm 40, 386–393 (2018). https://doi.org/10.1007/s11096-018-0590-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-018-0590-3